Other Lipid Biomarkers

Author(s):

Key Takeaways

Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Implementation is inconsistent due to barriers like lack of awareness and time constraints in clinical settings.
Strategies to enhance uptake include routine integration, electronic health record reminders, and education for providers and families.

Panelists discuss how comprehensive lipid assessment should include VLDL, HDL, triglycerides, and relevant ratios as they provide valuable insights into cardiovascular risk beyond LDL-C measurements alone.

EP: 1.Prevalence of Cardiovascular Disease

EP: 2.AHA Guidelines and Patient Mortality

EP: 3.Role of LDL-C in ASCVD

EP: 4.Pediatric Lipid Screening

EP: 5.Lp(a) in Pediatrics

EP: 6.DCRM Recommendations for Lipid Testing and LDL-C Management

Now Viewing

EP: 7.Other Lipid Biomarkers

EP: 8.LDL-C Management in Subpopulations

EP: 9.Cost Considerations for LDL Reduction Therapies

EP: 10.Familial Hypercholesterolemia Testing

EP: 11.Role of Lp(a) in ASCVD Risk

EP: 12.Data Analysis: State of LDL-C Control in Patients With ASCVD

EP: 13.Pediatric Lipid Treatment Recommendations

EP: 14.International Lipid Expert Panel Recommendations and RACING Trial

Video content above is prompted by the following:

What considerations do you give to other lipid biomarkers, such as very low-density lipoprotein (VLDL), high-density lipoprotein (HDL), and triglycerides? Should clinicians be looking at ratios, such as TC/HCL or LDL/HDL?